Key result
Engineered spider toxin analogues increase potency and enhance selectivity at specific hNaV subtypes.
Why the study?
Structure-function analysis of NaV-inhibiting spider toxins at multiple human NaV subtypes beyond NaV1.7 is warranted to develop selective inhibitors for emerging therapeutic targets.
Designed analogues of spider toxin Ssp1a show improved potency and subtype selectivity for human voltage-gated sodium channels, providing leads for pain and epilepsy therapeutics.
Preclinical leads for selective NaV modulators in pain/epilepsy; leaves open translation to human therapies.
The structure-function and optimization studies of Na V -inhibiting spider toxins have focused on developing selective inhibitors for peripheral pain-sensing Na V 1.7. With several Na V subtypes emerging as potential therapeutic targets, structure-function analysis of Na V -inhibiting spider toxins at such subtypes is warranted. Using the recently discovered spider toxin Ssp1a, this study extends the structure-function relationships of Na V -inhibiting spider toxins beyond Na V 1.7 to include the epilepsy target Na V 1.2 and the pain target Na V 1.3. Based on these results and docking studies, we designed analogues for improved potency and/or subtype-selectivity, with S7R-E18K-rSsp1a and N14D-P27R-rSsp1a identified as promising leads. S7R-E18K-rSsp1a increased the rSsp1a potency at these three Na V subtypes, especially at Na V 1.3 (∼10-fold), while N14D-P27R-rSsp1a enhanced Na V 1.2/1.7 selectivity over Na V 1.3. This study highlights the challenge of developing subtype-selective spider toxin inhibitors across multiple Na V subtypes that might offer a more effective therapeutic approach. The findings of this study provide a basis for further rational design of Ssp1a and related NaSpTx1 homologs targeting Na V 1.2, Na V 1.3 and/or Na V 1.7 as research tools and therapeutic leads.
No takes yet. Share an insight, caveat, or question.
Dongol et al. (2023) studied NaV channel dysfunction (pain, epilepsy). Ssp1a spider toxin analogues (S7R-E18K-rSsp1a and N14D-P27R-rSsp1a) vs. Wild-type rSsp1a was evaluated on Potency (IC50) and subtype-selectivity at hNaV1.2, hNaV1.3, and hNaV1.7. The engineered spider toxin analogue S7R-E18K-rSsp1a increased potency at hNaV1.2, hNaV1.3, and hNaV1.7, while N14D-P27R-rSsp1a enhanced hNaV1.2/1.7 selectivity over hNaV1.3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: